PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8859008-14 1996 Hexamethonium or L-NNA (but not atropine) reduced VIP release; CCK8 still enhanced it. Hexamethonium 0-13 vasoactive intestinal peptide Canis lupus familiaris 50-53 9350974-9 1997 Pancreatic VIP release during VNS was not affected by atropine, whereas ganglionic blockade with hexamethonium nearly abolished the VIP response to VNS (p<0.005 vs control), suggesting that VIP is a postganglionic neurotransmitter in the dog pancreas. Hexamethonium 97-110 vasoactive intestinal peptide Canis lupus familiaris 132-135 9350974-9 1997 Pancreatic VIP release during VNS was not affected by atropine, whereas ganglionic blockade with hexamethonium nearly abolished the VIP response to VNS (p<0.005 vs control), suggesting that VIP is a postganglionic neurotransmitter in the dog pancreas. Hexamethonium 97-110 vasoactive intestinal peptide Canis lupus familiaris 132-135 7977833-5 1994 The increases in heart rate and lymph VIP output were blocked by hexamethonium. Hexamethonium 65-78 vasoactive intestinal peptide Canis lupus familiaris 38-41 8113980-8 1994 Hexamethonium and atropine abolished tonic VIP output, leaving intact motility responses to PL017 and DPDPE. Hexamethonium 0-13 vasoactive intestinal peptide Canis lupus familiaris 43-46 8089398-2 1994 In blood-perfused ileum, ACh (2-200 nmol/min) produced a dose-dependent increase in venous VIP output, which was slightly reduced by hexamethonium (10 nmol/min) and blocked by hexamethonium and atropine (10 nmol/min) in combination. Hexamethonium 133-146 vasoactive intestinal peptide Canis lupus familiaris 91-94 8089398-2 1994 In blood-perfused ileum, ACh (2-200 nmol/min) produced a dose-dependent increase in venous VIP output, which was slightly reduced by hexamethonium (10 nmol/min) and blocked by hexamethonium and atropine (10 nmol/min) in combination. Hexamethonium 176-189 vasoactive intestinal peptide Canis lupus familiaris 91-94 8089398-4 1994 ACh-induced VIP output was decreased slightly by hexamethonium (0.1 mM), and blocked by atropine (0.1 mM) or pirenzepine (0.1 mM). Hexamethonium 49-62 vasoactive intestinal peptide Canis lupus familiaris 12-15 8089398-5 1994 Dimethylphenylpiperazinium (0.1 mM) also caused a small increase in VIP output sensitive to hexamethonium in the ileal tissues containing either the submucous or myenteric plexus. Hexamethonium 92-105 vasoactive intestinal peptide Canis lupus familiaris 68-71 8134298-4 1993 A combination of atropine and hexamethonium eliminated the PYY-induced decrement in VIP output and left motor excitation unchanged. Hexamethonium 30-43 vasoactive intestinal peptide Canis lupus familiaris 84-87 8304456-8 1994 Atropine reduced and hexamethonium nearly abolished VIP output. Hexamethonium 21-34 vasoactive intestinal peptide Canis lupus familiaris 52-55 2475029-3 1989 VIP release was markedly reduced by tetrodotoxin, perfusion with Ca-free medium, or by hexamethonium but not by atropine. Hexamethonium 87-100 vasoactive intestinal peptide Canis lupus familiaris 0-3 7439634-6 1980 Tetrodotoxin and hexamethonium, but not atropine, inhibited oxytocin-stimulted release of VIP by 80% and 60% respectively. Hexamethonium 17-30 vasoactive intestinal peptide Canis lupus familiaris 90-93 7439634-8 1980 Hexamethonium strongly inhibited neostigmine-stimulated release of VIP. Hexamethonium 0-13 vasoactive intestinal peptide Canis lupus familiaris 67-70